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Abstract
Context—The Palliative Care Research Cooperative group (PCRC) is the first clinical trials 
cooperative for palliative care in the United States.
Objectives—To describe barriers and strategies for recruitment during the inaugural PCRC 
clinical trial.
Methods—The parent study was a multi-site randomized controlled trial enrolling adults with 
life expectancy anticipated to be 1–6 months, randomized to discontinue statins (intervention) vs. 
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to continue on statins (control). To study recruitment best practices, we conducted semi-structured 
interviews with 18 site Principal Investigators (PI) and Clinical Research Coordinators (CRC), and 
reviewed recruitment rates. Interviews covered 3 topics – 1) successful strategies for recruitment, 
2) barriers to recruitment, and 3) optimal roles of the PI and CRC.
Results—All eligible site PIs and CRCs completed interviews and provided data on statin 
protocol recruitment. The parent study completed recruitment of n=381 patients. Site enrollment 
ranged from 1–109 participants, with an average of 25 enrolled per site. Five major barriers 
included difficulty locating eligible patients, severity of illness, family and provider 
protectiveness, seeking patients in multiple settings, and lack of resources for recruitment 
activities. Five effective recruitment strategies included systematic screening of patient lists, 
thoughtful messaging to make research relevant, flexible protocols to accommodate patients’ 
needs, support from clinical champions, and the additional resources of a trials cooperative group.
Conclusion—The recruitment experience from the multi-site PCRC yields new insights into 
methods for effective recruitment to palliative care clinical trials. These results will inform 
training materials for the PCRC and may assist other investigators in the field.
Keywords
palliative care; recruitment; research networks; clinical trials
INTRODUCTION
Research is necessary to guide high quality palliative care and the selection of treatments to 
maximize health outcomes for these patients and their families. Palliative care research 
encompasses patients with diverse diagnoses, all with serious and incurable illnesses which 
are potentially life-limiting. In the period of illness leading up to death, treatments must be 
chosen with parsimony, maximizing benefit while avoiding harms. Studies relevant to 
hospice and palliative care comprise <1% of clinical trials, and seriously ill patients are 
systematically excluded from other research.1 Few investigators have the practical and 
methodological expertise to conduct these studies, making it critical to disseminate 
successful research strategies.2,3
Palliative care clinical trials must enroll sufficient numbers of patients for scientific validity, 
yet participation is not easy for this population.4 Recruitment is a major challenge – 80% of 
palliative care investigators awarded funding from the National Cancer Institute and the 
National Institute of Nursing Research reported recruitment barriers, and participation rates 
of 50% or less are common.32,5
Barriers to recruitment to palliative care trials are ethical and practical in nature. Patients and 
families become physically and emotionally vulnerable in the face of serious illness, adding 
potential burden, or even risk, to research. Practical concerns include communication 
barriers such as expressive aphasia or delirium, or limited mobility or energy.6 Ethical 
concerns – which may influence approval by Institutional Review Boards, include patient 
vulnerability, high rates of cognitive impairment and emotional distress challenging true 
informed consent, clinician-researcher role conflicts, and research burden.7,8
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Clinical trial networks are one mechanism to pool expertise and enhance research 
productivity and quality.9 The first Palliative Care Research Cooperative Group (PCRC) in 
the United States was initiated in 2010 with foundational funding from the National Institute 
of Nursing Research that started in January 2011 (NINR; UC4NR012584). The PCRC’s 
overarching mission is to develop scientific methods that lead to meaningful evidence for 
decreasing the suffering of patients with advanced or potentially life-limiting illnesses, and 
their caregivers. Specific objectives include expanding research capacity, conducting high 
impact clinical trials, and training new investigators. (Figure) The conduct of the PCRC’s 
inaugural multi-site clinical trial provided a unique opportunity to examine effective 
strategies for enrolling seriously ill patients. We interviewed investigators and research 
coordinators from 9 participating PCRC sites in order to describe barriers and strategies for 
recruitment to palliative care clinical trials.
METHODS
To understand best practices for recruitment to palliative care clinical trials, we interviewed 
key research personnel from PCRC sites. Data collection consisted of semi-structured 
interviews with each site Principal Investigator (PI) and Clinical Research Coordinator 
(CRC) for PCRC member sites, and review of site-specific recruitment rates.
Rationale and Design of the Inaugural PCRC Clinical Trial
The PCRC is a clinical trials cooperative group composed of investigators with a shared 
vision that excellent palliative care at the bedside is contingent on best evidence and a 
scientific underpinning for clinical care.10 At the time of this investigation, all sites were 
active participants in the PCRC’s inaugural clinical trial: “A multisite randomized controlled 
trial of continuing vs. discontinuing statins in palliative care patients with limited 
prognosis.” Statins reduce risk of future cardiovascular events for patients with 
hyperlipidemia.11 Studies demonstrate lesser or no cardiovascular risk benefits in 
populations with severe co-morbid illnesses.12,13,14,15 Statins are frequently continued in 
serious or life-limiting illness, in the absence of evidence for safe discontinuation.16,17,18,19 
Observational studies provide varied evidence for the safety of statin discontinuation.20,21 
The risks vs. benefits of statins for palliative care patients remains an area of compelling 
clinical uncertainty.
The parent study was a non-blinded multi-site randomized controlled trial enrolling adults 
with limited life expectancy anticipated to be 1–6 months, on statins for primary or 
secondary prevention. Persons with cardiovascular events in the preceding 6 months were 
excluded, as were those whose primary physicians found contraindications to safe 
enrollment. Participants were randomized 1:1 to discontinue statins (intervention) vs. to 
continue statins (control), stratified by site and cardiovascular history. Enrolled patients 
were followed for up to 1 year with interviews and medical record reviews. The primary 
outcome was 60-day survival; secondary outcomes included cardiovascular events, 
symptoms, health related quality of life, polypharmacy, costs, and patient satisfaction with 
care. A standard research protocol was followed at all sites; site-specific IRB review was 
required and recruitment methods had to meet these human subjects standards.
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Methods for Semi-structured Recruitment Interviews
Each of the 18 site PIs and CRCs at the 9 active enrollment sites were eligible for 
interviews, which were conducted as recruitment for the statin trial ended. The interview 
script was semi-structured to participants to explain stated barriers or strategies. Interview 
items were developed for the unique objectives of this study, and covered 3 topics – 1) 
successful strategies used for recruitment to the statin protocol and other palliative care 
research, 2) barriers to recruitment, and 3) optimal roles of the PI and CRC in recruitment 
for palliative care research. Participants described their experience and current level of 
involvement in palliative care research. Site PIs were interviewed by the investigators (JB, 
LCH), and site CRCs were interviewed by participating CRCs (LM, KW). All interviews 
were conducted by telephone, using the interview script with probes to explore individuals’ 
answers to each question. All sites also provided data on actual recruitment of research 
subjects for the statin discontinuation clinical trial. Participants gave verbal informed 
consent; the study was judged exempt from review by the University of North Carolina 
Institutional Review Board.
Analysis
All interviews were recorded and professionally transcribed. Investigators used directed 
content analysis for theme identification, using the concepts of process barriers and 
facilitators and relevant research to guide initial codes.22,23 Investigators (LCH, JB, KW, 
LM, REB) independently sought themes in a subset of the transcripts, and initial themes 
were pooled and discussed until consensus was reached. Each participant was identified by 
role (PI or CRC) and by whether their site had recruited higher or lower than the average 
number of participants for all sites. Thematic grouping were examined for content on 
barriers and successful strategies, and representative quotes were selected.
RESULTS
All 18 eligible site PIs and CRCs completed interviews. In addition to palliative care, 
investigators’ specialties included geriatric medicine, general medicine and medical 
oncology. All site PIs and nearly all CRCs had prior research experience with seriously ill 
patients. Site PIs reported prior experience with between 2 and “more than 60” clinical 
trials. Investigators estimated spending 10–30% of their time on the statin protocol. All 
CRCs had prior experience conducting research with chronically or seriously ill patients, yet 
several were new to clinical trials. They reported spending 50–100% of their time on the 
statin protocol during active recruitment. The study protocol completed recruitment of 
n=381 patients on April 30, 3013. Site enrollment ranged from 1–109 participants, with an 
average of 25 enrolled per site.
Barriers
PIs and CRCs described five major barriers to palliative care research recruitment: difficulty 
finding eligible patients, patient illness, physician or caregiver protectiveness, demands of 
multiple settings, and scarce resources. (Table 1)
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First, they reported difficulty finding patients who meet the prognosis required for a 
palliative care trial. Patients frequently must meet prognostic criteria which are not routinely 
recorded in the medical record. CRCs compared screening hundreds or even thousands of 
medical records each week to searching for a “needle in a haystack.” By the time a patient 
was identified and approached, they might have become more ill or changed settings; as one 
CRC noted when finding patients from the hospital census, “It is really difficult identifying 
people who are eligible … they have already gone home, and then it turns into essentially a 
cold call.” Information on disease stage, functional status or anticipated life expectancy is 
recorded inconsistently, and is usually found in text notes rather than electronic records. 
Physicians tend to overestimate their own patients’ prognosis, which may contribute to lack 
of documentation.
The second and third themes identified barriers that were often conceptually linked. Patient 
illness severity resulted in symptoms that limited research participation. (Table 1) Patients 
who were in pain, had severe fatigue or nausea, simply felt overwhelmed by the demands of 
serious illness. Investigators or CRCs often discussed severity of illness and then linked it to 
the third theme of physician or caregiver protectiveness. Researchers approached family or 
nurses to learn if patients were able to discuss participation – and found these individuals 
were protective to the point of refusal on the patient’s behalf. Investigators and CRCs 
reported experiences with clinic physicians, hospice nurses and primary care doctors who 
would not permit recruiting visits, because they believed patients would be overly burdened 
by research participation.
A fourth theme was the logistic demands created by seeking patients who were in multiple 
healthcare settings. (Table 1) Patients with serious illness see multiple providers and 
frequently transfer from outpatient to inpatient or long-term care settings.24 Staff and 
investigators reported they had to establish recruitment procedures in many, rather than one 
clinical site, and each demanded additional time.
Finally, investigators discussed lack of resources, particularly personnel time, as an 
important fifth barrier to recruiting. They indicated that palliative care research required 
greater investments in personnel time than non-palliative care clinical trials. Participants 
also noted the need for systematic preparation and training of personnel to approach 
palliative care patients and families.
Effective Strategies for Recruitment
Participating site PIs and CRCs reported numerous strategies they found to be effective to 
recruit palliative care patients to the statin protocol, and to other studies. Themes for 
effective recruitment included effective screening, messaging, flexibility, clinical champions, 
and the benefits of the cooperative group.
Investigators used efficient approaches to screen large patient populations to find the small 
subset who met palliative care trial eligibility. Screening procedures typically involved daily 
review of hospital census or clinic schedules. (Table 2) While the need for screening 
techniques was universal, the approaches depended on site-specific knowledge. Hospice 
providers added a screening admission question to identify patients on statins, while one site 
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with an electronic clinical database paid for a systematic monthly query to find potentially 
eligible patients with scheduled clinic visits.
Palliative care researchers described careful messaging as a second critical recruitment 
strategy. Messaging about palliative care generally, and about a specific study protocol, was 
reported as essential to engage patients. They described the importance of content, including 
explanation of the meaningfulness of research and the concept of leaving a legacy by 
helping others with similar illness. CRCs were careful to include expressions of gratitude for 
patients’ willingness to help and share their time or opinions. (Table 2) In addition to careful 
content, communication style and interpersonal approach was considered equally important. 
CRCs emphasized having empathy, favoring in person rather than telephone approaches, use 
of simple and clear language to explain the study and sensitivity to body language.
Respondents also discussed the critical strategy of flexibility in recruitment. As the sample 
quotes in Table 2 illustrate, CRCs and PIs describe a multitude of ways to accommodate the 
needs of palliative care patients and caregivers. They designed protocols to permit greater 
time flexibility, and to permit the patients to control timing of study visits. In many 
examples, patients were allowed to control the location of interviews as well – in hospital 
rooms, clinics, or even in their own homes – to ensure comfort and convenience. In some 
examples, flexibility also meant allowing family surrogates to speak on the patient’s behalf, 
as one CRC noted “I let them know that if they are too tired to talk to me or if there is too 
much going on, I can also talk with anybody else that they designate … and so there are lots 
of different options.” This theme illustrated creative approaches used to reduce the burden of 
trial participation for palliative care patients, therefore making recruitment more feasible.
Another recruitment strategy was engagement of clinical champions who assisted with 
access to patient populations. Interview participants noted this as an essential role for a PI, 
who would cultivate relationships with clinical leaders and build enthusiasm for the trial. 
(Table 2) Champions were defined by their ability to give entrée to patients, but also by their 
willingness to introduce the trial to patients or make referrals. Typically this role began with 
the champion’s scientific interest in the study, but sometimes included incentives such as in-
service education, small gifts of food, or (rarely) payments for each successful patient 
referral.
Finally, some interview participants noted ways that the PCRC, as a research cooperative, 
was a resource to improve clinical trials recruitment. (Table 2) Comments focused on team-
based support, sharing and disseminated best practices in an on-going clinical trial, and 
learning together from successes.
Role of the PCRC to Enhance Recruitment
To wrap up each interview, respondents were asked if there was any systematic ways the 
Palliative Care Research Cooperative group could improve recruitment. Respondents’ 
suggestions included training for research staff and support for the role of site principal 
investigator. Suggestions for training research staff included sharing effective recruitment 
methods systematically, and rapid dissemination of new research protocols including 
specifics of recruitment. Respondents recommended that the PCRC promote and reward 
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engagement by principal investigators, including participation in regular teleconferences, 
shared methods to introduce palliative care concepts, and direct involvement in recruitment.
DISCUSSION
This study draws on the recruitment experience from the multi-site PCRC to gain new 
insights into methods for effective recruitment to palliative care clinical trials. This study 
compiles perspectives from experienced investigators and research staff on best practices to 
support recruitment of patients with life-limiting illness for research. To achieve this goal 
respondents reported use of screening strategies to find eligible patients, thoughtful 
messaging when approaching potential participants, built flexibility into protocols to 
facilitate participation, and cultivated relationships with clinical champions who endorsed 
the value of this research. Dissemination of these recruitment strategies can encourage future 
palliative care clinical trials.
This study adds to a small but critical body of empiric evidence for best practices in 
palliative care research methods. In a meta-synthesis of palliative care interventions, Evans 
found that poor recruitment and sample size insufficient to detect change was one of four 
common methodologic weaknesses in this body of research.25 Successful strategies 
highlighted in this review included 1) active and systematic screening for eligibility, 2) 
anticipating the gatekeeping concerns of family caregivers and clinicians, and 3) strategies 
to facilitate patient or caregiver participation, such as anticipating fatigue or burden. Indeed, 
successful recruitment programs can be instituted. Riopelle and colleagues completed a 
successful palliative care intervention study enrolling 400 (70%) of 561 eligible patients 
with advanced life-limiting illness.26 These investigators attributed effective recruitment to 
1) purposeful case-finding through physician prognostication, 2) interviewer training and 
support, 3) systematic and flexible strategies to minimize patient or caregiver burden, and 4) 
consistent interviewer-respondent assignment. Similarly, LeBlanc and colleagues described 
the successful accrual of 461 (76%) of 607 eligible patients in 26 months using a recruitment 
algorithm including, 1) systematic triage, 2) information booklets for stakeholders, 3) 
trained recruitment personnel, and 4) standardized wording in all communications.27 This 
approach was replicated in another palliative care study with similar outcomes.28 
Investigators acknowledge the importance of clinical trial recruitment methods, in the wake 
of concerns regarding poor accrual to protocols.29,30,31 The National Institutes of Health 
acknowledges recruitment as a major threat to science benefitting seriously ill patients, and 
the National Cancer Institute disseminates best practices in cancer clinical trials recruitment 
through its AccrualNet website.32,33
Our study should be interpreted with certain considerations in mind. Participants are among 
the most experienced palliative care investigators in the United States, yet may not represent 
the views of investigators with similar experience outside the PCRC. Recruitment 
approaches varied by site, since site-specific IRB requirements applied and site investigators 
recruited in diverse settings and populations. All participants were actively recruiting for a 
single protocol, and particular demands of this protocol and the early experience of a 
cooperative group may skew their responses. We did not study methods of retention, a 
related methods concern for palliative care research.
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Our findings have important implications for the design and funding of future palliative care 
clinical trials. First, study protocols have to be written with some latitude in recruitment 
procedures, to accommodate the needs of this vulnerable patient population. Flexibility in 
timing, site and pacing of research is necessary to facilitate participation while mitigating 
burdens. Second, research budgets should be adapted to ensure adequate personnel time – 
from investigators and research staff – to be dedicated to recruitment activities such as 
identifying champions, screening large patient populations, and approaching patients and 
families in a manner respectful of their needs. Third, investigators should anticipate the need 
to train themselves and their research staff on effective recruitment strategies.
The results of this study will be used within the PCRC to develop standardized training 
materials for palliative care recruitment methods. Given the paucity of experienced 
palliative care investigators and staff, it may be more effective to provide training in 
research methods using a centralized repository of materials. Future trials within the PCRC 
will emphasize engagement with junior investigators and dissemination of effective methods 
to member investigators. This repertoire of training tools in palliative care methods, 
including approaches to enhance recruitment, will be accessible and serve as a resource to 
the larger field of palliative care research.
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Table 1
Themes and Example Quotations for Palliative Care Recruitment Barriers
Themes Examples
Barrier: Finding eligible 
patients
“Even though I have screened so many thousands of charts, there just aren’t people who meet our specifications 
so that has been a huge challenge ….” –high/CRC
“It is hard to screen on prognosis. It is also hard to know what their performance status is.” –low/PI
“It is really difficult identifying people who are eligible … they have already gone home, and then it turns into 
essentially a cold call and really they are not as receptive to a phone call as they would be an in person visit.” –
high/CRC
“There are few oncologists that think their patients are always going to live forever.…” –high/PI
Barrier: Patient illness “Most of them will tell me, okay can you come back because I am not doing too well now, and I tell them okay I 
will come back and then when I go back, they would ask me to come back again; I am still unwell.” –low/CRC
“I think the biggest barrier is these people are sick, they are in the hospital not because they wanted to come in, 
they do not feel good, and a lot of times I think patients just simply did not feel good, they did not want to talk, 
they were tired.” –high/CRC
Barrier: Physician / 
caregiver protectiveness
“This is a vulnerable population, and often times you do not just interact with the patient, you interact with the 
family, the providers who may, you know, have an emotional attachment to the patient.” –high/CRC
“I went to each research group and they were all willing to put patients on but when it comes down to that day in 
their clinic, it is very hard for them to be able to do that because they feel like they are always giving patient bad 
news; so if the patients are getting bad news, I do not even get a chance to get into the door.” –low/CRC
“Hospice nurses actually can be a barrier and I think the biggest reason is they feel on some level it is intrusive to 
a patient or that it is going to take too much time and the patient is already vulnerable or in a weakened state … 
some that tend to say ‘oh no my patients cannot do it right now, they are declining too fast.’” –high/PI
“… on reasons for refusal, one reason seems to be when the patient’s family members have concerns about 
patient’s participation in the study” –low/CRC
“We have had a few primary care physicians who have said that their patients are too sick to participate, I mean 
too burdened by illness to participate.” –high/PI
Barrier: Demands of 
multiple settings
“I think we have been most successful in sites where there is a committed investigator doing enough hands on 
clinical stuff so they have access to the patients themselves. We have been less successful in settings where we 
are fully dependent on CRC contacting the primary physician” –high/PI
“It is very hard to see someone in clinic. The waiting room is not a good area and if they get in the back … you 
do not want to disrupt their clinic flow and then when they are done, they are done, they want to go home.” –
high/PI
“We found that our poor CRC was spending so much time sitting in this clinic, sitting in that clinic, … This is 
where we sat down after I think was probably a couple of months, I said okay … are we demonstrating that we 
are getting return on investment, … and the places where it was not, we just pulled out.” –high/PI
Barrier: Resources “I feel like I do not have a lot support on the ground level.” –high/CRC
“We need more staff.” –High, PI
“We need to be able to get paid even when we have an off month recruiting because things do ebb and flow and 
that is very problematic for us.” –High, PI
“Underwriting the clinical research nurse … In order to get out there and start doing this it can’t just be 
recruitment dependent in the early stages” – Low, PI
“I really think that there could have been a little more planning done to aid in the beginning recruitment process 
for the initial sites.” –high/CRC
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Table 2
Themes and Example Quotations for Palliative Care Recruitment Strategies
Themes Examples
Strategy: Effective Screening “We have phenomenal electronic medical record system and each day I can go in and review every patient 
in the hospital who is under the medical service and the palliative care service and I simply click on the med 
list, find any patient who is on statins, find who their attending physician is, contact them, ask if they would 
be okay with me contacting their patient to discuss the study.” –high/CRC
“If somebody is on a statin then we have added a question to our electronic health records for the 
admissions nurse to ask if they would be willing to be contacted by the research department for a study 
about their statin.” –high/PI
“On the front end side of things when we are identifying where we are going to be recruiting from and the 
processes for recruiting from each site that I have as the PI had a lot of involvement with making the 
outreach to my colleagues to gain entry with the CRC.” –high/PI
“What we have done to at least help identify participants is to use our electronic database house to help us 
screen people that meet criteria the way it is set. So we query the database twice a week as that helps 
identify people on that screen per our eligibility criteria.” –low/PI
Strategy: Messaging “I talk about the study in general, but then when talking about research, a lot of people really are at 
crossroads in their disease process … and being able to give back and help someone else is sometimes a 
good incentive for participation.” –high/CRC
“I do emphasize that it is research because it has benefits and risks but again I am not using them as a 
guinea pig because they are not, it is volunteer. I express appreciation for them every single time. Every 
time I talk to them on the phone, I make sure that they know that I am appreciative that they took their time 
off to talk to me, and I thank them at the end of every call, you know to remind them that information that 
we received is helpful not only for them but for somebody down the road.” –high/CRC
“Usually when I am first meeting them, I reach out and shake their hand, I hold their hand, I am up close 
and personal with them, get a chair and sit down and start going through the study.” –high/CRC
“I think it is important to talk at a level that is understandable for everybody, so not using a lot of jargon and 
speaking in a way that anybody could understand, that they do not need to be a health professional to 
understand what I am trying to say.” –high/CRC
Strategy: Flexibility “I let them know that if they are too tired to talk to me or if there is too much going on, I can also talk with 
anybody else that they designate … and so there are lots of different options, … so I think that is comforting 
to them, … even though they have a lot going on, there is a way that they can provide information that 
might help somebody else.” -high/CRC
“I get at least 50%, maybe more, of all the people I enroll in the study by going to their home. They are 
comfortable in their own space. I can sit down with them at the table and discuss the study in conversational 
terms.” –high/CRC
“I think that being flexible and sometimes it may take several tries or extended over a couple of different 
visits to get all the information. It may be somebody needs to first hear about the study and then think about 
it and then come back. Not thinking that you can just walk in and get this done in half an hour.” –high/PI
Strategy: Clinical Champions “We try to get them (providers) excited about the study, we try to get them excited about helping with a 
relationship, … so this is just one more aspect of another person checking up on their patient and potentially 
sharing information that is good for them, so we try to make the providers excited too, and that has been 
beneficial.” -high/CRC
“What I found to be most useful for each clinical area is to start by figuring out who the key people are and 
talking to them first, either one on one or small groups about the study, what does it mean, why are we 
doing it and get their input into how do we then either access the population or introduce it to the other 
clinicians.” –high/PI
“I try to take time out to ask how they are doing and listen to what they say, … I try to make sure that they 
know how appreciative I am of that relationship because they are busy, they are seeing lots of patients and 
they have much more direct patient contact than I do, so they are having to deal with the heartache of 
somebody who is going through a medical crisis or pain crisis or psychosocial crisis … when they refer a 
patient, I make sure that I say ‘we appreciate your referral so much. Thank you for thinking of us’.” –
high/CRC
“It is important for not only PIs but other providers to be engaged and have some sort of involvement with 
the study. An example is outside hospices or inpatient units. … we have had the most success in areas 
where the providers, nursing staff are actually kind of excited about us seeing their patients.” –high/CRC
“Identifying a champion is essential to address barriers that you meet with recruitment, educating the staff 
person who works within the palliative care system and first contacts patients for the study.” –low/CRC
Strategy: Cooperative Group 
Resources
“I think the teleconferences have been a great asset so that coordinators of each site know some working 
strategies and some of them are able to identify some nuances at other sites that you may be facing. I think 
the telephone conferences are major plus.” –low/CRC
“I think having support from your other team members is extremely helpful and honestly if you have that 
that would improve recruitment and all of the above.” –high/CRC
“Monthly research meetings of the investigators are really important. I think it has to be mandatory, because 
working with a lot of sites some of them do research, some of them do not, but you do not know how 
essential that is until you have tried to work without it.” –high/PI
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